Honokiol in cancer: Roles in enhancing combination therapy efficacy and preventing post-transplant malignancies

• DOI: 10.36922/td.8152
• Publication Date: 2025-05-08T01:55:37Z
• Authors: Laxminarayan Rawat; Raghu Solanki; Rahul Kumar; Soumitro Pal; Akash Sabarwal
• Keywords: Honokiol; Cancer Therapy

Therapeutic resistance remains a significant challenge in cancer treatment, often resulting relapse and poor outcomes. Conventional chemotherapies, such as cisplatin paclitaxel, are frequently undermined by the development of chemoresistance systemic toxicity. Targeted therapies, receptor tyrosine kinase (RTKs) inhibitors monoclonal antibodies (mAbs), offer better specificity but face over time. Combination therapies being explored to improve efficacy mitigate resistance. Honokiol, biphenolic natural compound derived from Magnolia species, has emerged potential adjunct combination due its anti-cancer, anti-inflammatory, immunomodulatory properties. It enhances RTK inhibitors, cabozantinib erlotinib, mAbs, cetuximab. Notably, honokiol combined with mAbs shown promise pre-clinical studies reactivating immune system reducing tumor growth resistant models. In addition, aids post-transplant prevention modulating responses, progression, lowering required dose immunosuppressants, cyclosporine A rapamycin. Pre-clinical renal cell carcinoma (RCC), head neck squamous (HNSCC), non-small lung emphasize overcome Despite promising evidence, further clinical needed validate viable therapies. While several reviews have focused on effects alone, there is lack comprehensive examining other This review aims fill this gap offering critical insights into role candidate for therapy.